姓名
王爱萍
出生年月
1978年11月


性别
女
专业
药剂学

职称
副教授
学位
博士

是否博导
否
是否硕导
是

电子信箱
wangaiping@luye.com
联系电话




研究方向及主要研究内容

研究方向为长效缓控释制剂、经鼻脑靶向制剂等新型给药系统研究。
主要研究内容包括罗替戈汀等中枢神经系统药物长效缓释微球的研究；长效微晶缓释制剂的研究；经鼻脑靶向制剂的研究。

荣誉及学术兼职（限填5项）



承担的主要科研课题（限填5项）

序号
课题名称
课题来源
是否课题负责人

1
基于持续多巴胺能刺激治疗帕金森病的长效释药系统的构建及其机制研究（ZR2013HQ009）
山东省自然基金
是

2
基于冰片药引的双级经鼻脑靶向纳米递药系统的构建及治疗帕金森病研究（ZR2017LH076）
山东省自然基金
是

3
基于树枝状聚合物PAMAM的葛根素眼部递药系统的构建及其角膜作用机制研究（**）
国家自然基金
否

4
注射用石杉碱甲长效缓释微球（2009ZX09102-125）
国家“十一五”科技重大专项
否








重要奖项和专利情况（限填5项）

序号
奖项或专利名称
奖项类别或专利号







发表论文、著作情况（限填10篇）

(1) Liuxiang Chu#, Aiping Wang#*, Ling Ni, Xiuju Yan, Yina Song, Mingyu Zhao, Kaoxiang Sun*, Hongjie Mu, Sha Liu, Zimei Wu, Chunyan Zhang. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug delivery, 2018, 25(1): 1634–1641
(2) Dongyu Duan#, Aiping Wang#, Ling Ni, Liping Zhang, Xiuju Yan, Ying Jiang, Hongjie Mu, Zimei Wu, Kaoxiang Sun*, Youxin Li*. Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. International Journal of Nanomedicine, 2018:13 1831–1840.
(3) Xiuju Yan#, Lixiao Xu#, Chenchen Bi, Dongyu Duan, Liuxiang Chu, Xin Yu, Zimei Wu, Aiping Wang*, Kaoxiang Sun*. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. International Journal of Nanomedicine, 2018, 13:273-281.
(4) Ying Jiang, Xuemei Zhang, Hongjie Mu, Hongchen Hua, Dongyu Duan, Xiuju Yan, Yiyun Wang, Qingqing Meng, Xiaoyan Lu, Aiping Wang*, Wanhui Liu, Youxin Li, Kaoxiang Sun*. Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease., 2018, 25(1):143-152.
(5) Qingqing Meng#, Aiping Wang#*, Hongchen Hua, Ying Jiang, Yiyun Wang, Hongjie Mu, Zimei Wu, Kaoxiang Sun*. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. International Journal of Nanomedicine, 2018, 13:705–718.
(6) Yongchao Chu, Ning Chen, Huajun Yu, Hongjie Mu, Bin He, Hongchen Hua, Aiping Wang*, Kaoxiang Sun*. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles. International Journal of Nanomedicine, 2017, 12:1353-1368.
(7) Chenchen Bi#, Aiping Wang#, Yongchao Chu, Sha Liu, Hongjie Mu, Wanhui Liu, Zimei Wu, Kaoxiang Sun*, Youxin Li*. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. International Journal of Nanomedicine, 2016, 11:6547-6559.
(8) Aiping Wang, Yanxiang Liu, Rongcai Liang, Xuemei Zhang, Kaoxiang Sun, Zimei Wu, Wanhui Liu*. Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study. Saudi Pharmaceutical Journal, 2016, 24(3):363–370.
(9) Aiping Wang, Rongcai Liang, Wanhui Liu, Chunjie Sha, Youxin Li, Kaoxiang Sun*. Effect of palmitic acid on the characteristics and release profiles of rotigotine-loaded microspheres. Pharmaceutical Development and Technology, 2016, 21(1):3-7.
(10) Aiping Wang#, Lexi Wang#, Kaoxiang Sun, Wanhui Liu, Chunjie Sha, Youxin Li*. Preparation of rotigotine loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats. Pharmaceutical Research, 2012, 29(9):2367-2376.